No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

The study, published Jan. 20 in The Lancet Infectious Diseases, found the vaccine to be 78% effective against RSV infection, 79% effective against emergency department and urgent care visits and 80% ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

Marc Watkins, M.D., chief medical officer at Kroger Health, discusses RSV and how people can protect themselves and their ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...

Moderna is set to receive $590m in funding from the HHS to expedite the development of mRNA-based pandemic influenza vaccines ...

mRNA vaccines have emerged as a major scientific breakthrough in ... to elicit immune responses to these two distinct cancer ...